DMPI DelMar Pharmaceuticals Inc.

0.72
+0.04  (+5%)
Previous Close 0.68
Open 0.68
Price To Book -2.77
Market Cap 8,199,708
Shares 11,388,483
Volume 1,842,367
Short Ratio
Av. Daily Volume 360,056
Stock charts supplied by TradingView

NewsSee all news

  1. DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083

    SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today

  2. DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

    SAN DIEGO, Oct. 24, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  3. MicroCap Rodeo Investor Conference Lineup for October 15 and 16 - 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16th, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap

  4. DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time

    SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  5. DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 enrolment to be completed 4Q 2020. Update due at the Society of Neuro-Oncology meeting November 22, 2019.
VAL-083
MGMT-unmethylated newly diagnosed Glioblastoma Multiforme (GBM)
Phase 2 enrolment to be completed 4Q 2020. Update due at the Society of Neuro-Oncology meeting November 22, 2019.
VAL-083
MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Latest News

  1. DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083

    SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today

  2. DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

    SAN DIEGO, Oct. 24, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  3. MicroCap Rodeo Investor Conference Lineup for October 15 and 16 - 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16th, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap

  4. DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time

    SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  5. DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  6. DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

    SAN DIEGO, Sept. 10, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  7. DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria

    SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  8. DelMar Pharmaceuticals Relocates Headquarters to San Diego, California

    SAN DIEGO, Sept. 4, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  9. DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials

    VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the

  10. Thinking about buying stock in Aurora Cannabis, American Express, Walt Disney Co, DelMar Pharmaceuticals, or Tilray?

    NEW YORK, Aug. 26, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AXP, DIS, DMPI, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the